Dr. Htut on Immunotherapy in Multiple Myeloma – OncLive
|
Dr. Htut on Immunotherapy in Multiple Myeloma
OncLive Htut says that he has a vested interest in immunotherapy—using PD-1/PD-L1 inhibitors to modify a patient's immune system. Thus far, there has been a trial using the PD-1 inhibitor pembrolizumab (Keytruda) in myeloma. Unfortunately, there were some … |
